Search: (WFRF:(Yale Jean François)) >
Efficacy of lixisen...
Efficacy of lixisenatide in patients with type 2 diabetes : A post hoc analysis of patients with diverse β-cell function in the GetGoal-M and GetGoal-S trials
-
- Yabe, Daisuke (author)
- Kobe university
-
- Ambos, Anu (author)
- North Estonia Medical Center (Mustamäe Hospital)
-
- Cariou, Bertrand (author)
- Nantes University Hospital
-
show more...
-
- Duvnjak, Lea (author)
- University of Zagreb
-
- Evans, Marc (author)
- University Hospital Llandough
-
- González-Gálvez, Guillermo (author)
- Jalisco Institute of Diabetes and Obesity Research SC
-
- Lin, Jay (author)
- Novosys Health
-
- Nikonova, Elena V. (author)
- Artech Information Systems, LLC
-
- de Pablos-Velasco, Pedro (author)
- University of Las Palmas de Gran Canaria
-
- Yale, Jean François (author)
- McGill University
-
- Ahrén, Bo (author)
- Lund University,Lunds universitet,Medicin, Lund,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Medicine, Lund,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2016
- 2016
- English.
-
In: Journal of Diabetes and its Complications. - : Elsevier BV. - 1056-8727. ; 30:7, s. 1385-1392
- Related links:
-
http://dx.doi.org/10... (free)
-
show more...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Aims: To evaluate the impact of β-cell function on the efficacy of lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes (T2D). Materials and methods: In this post hoc analysis, patients from the Phase 3 GetGoal-M and GetGoal-S clinical trials randomized to lixisenatide 20. μg once daily were stratified into quartiles by baseline β-cell function, as measured by the secretory units of islet in transplantation (SUIT) index. Results: Patients (N = 437) were distributed evenly among SUIT index quartiles 1 to 4 (lowest to highest β-cell function). Clinical outcomes improved from baseline across all SUIT quartiles; mean changes at week 24 were: glycated hemoglobin (HbA1c; % [mmol/mol]), -0.99 (-10.8), -0.87 (-9.5), -0.86 (-9.4), -0.83 (-9.1); and postprandial plasma glucose (PPG; mmol/L), -7.9, -5.6, -5.5, -4.3 (overall effect . P .
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Hematologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Hematology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Keyword
- Antidiabetic drug
- Beta cell
- GLP-1 analog
- Glycemic control
- Type 2 diabetes
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database
- By the author/editor
-
Yabe, Daisuke
-
Ambos, Anu
-
Cariou, Bertrand
-
Duvnjak, Lea
-
Evans, Marc
-
González-Gálvez, ...
-
show more...
-
Lin, Jay
-
Nikonova, Elena ...
-
de Pablos-Velasc ...
-
Yale, Jean Franç ...
-
Ahrén, Bo
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Hematology
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Endocrinology an ...
- Articles in the publication
-
Journal of Diabe ...
- By the university
-
Lund University